会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明专利
    • METHOD AND SYSTEM FOR CONTROLLED INFUSION OF THERAPEUTIC SUBSTANCES
    • NZ592323A
    • 2012-05-25
    • NZ59232307
    • 2007-09-18
    • BAXTER HEALTHCARE SABAXTER INT
    • MOUBAYED AHMED-MAHERHYMAN OSCAR EWHITE DAVID NWILSON LARRY LSTEVENSON JOHN WMOUBAYED JAY G
    • G06F19/00A61M5/172
    • An infusion system for determining the infusion profile having a number of infusion steps for infusing an infusate into the body of a human or animal subject is disclosed. The system comprises a programmable controller and a pump and the system operates by the steps of A) assigning to the controller the following parameters i) total infusate volume; ii) total number of infusion steps; iii) time duration per infusion step, iv) maximum infusion rate, v) initial infusion rate, vi) incremental increase in infusion rate and vii) ramp rate; B) the controller calculating a first infusion step having i) a ramping segment wherein the infusion rate increases at the assigned ramp rate from zero to the assigned initial infusion rate and ii) a terminal segment; C) the pump co-operating with the controller to perform the first infusion step with the infusion continuing at approximately the assigned initial infusion rate until the assigned time duration has been reached; D) the controller calculating a volume of infusate delivered during the preceding infusion step; E) the controller calculating the remaining volume of infusate to be infused to deliver the assigned total infusate volume; F) the controller calculating an additional infusion step based on the remaining volume of infusate to be infused and the volume of infusate delivered during the preceding infusion step, the additional infusion step having: i) a ramping segment wherein the infusion rate increases at the assigned ramp rate from the infusion rate of the terminal portion of the preceding infusion step to a new infusion rate that is equal to the infusion rate of the terminal portion of the preceding infusion step plus the incremental increase in infusion rate with the new infusion rate not exceeding the assigned maximum infusion rate and ii) a terminal segment; G) the pump co-operating with the controller to perform the additional infusion step wih the infusion continuing at approximately the new infusion rate until the assigned time duration or the assigned total infusate volume has been reached; and H) repeating Steps D through G until the assigned total infusate volume has been delivered.
    • 9. 发明专利
    • METHOD AND SYSTEM FOR CONTROLLED INFUSION OF THERAPEUTIC SUBSTANCES
    • NZ575801A
    • 2011-12-22
    • NZ57580107
    • 2007-09-18
    • BAXTER INTBAXTER HEALTHCARE SA
    • MOUBAYED AHMED-MAHERHYMAN OSCAR EWHITE DAVID NWILSON LARRY LSTEVENSON JOHN WMOUBAYED JAY GTHOMAS LINDA
    • G06F19/00A61M5/172
    • A system for administering substance to a subject comprises a pump (10a) including a housing, a controller (14) that is in communication with the pump and issues control signals to the pump, a user interface external to the pump housing and configured to present queries to the subject regarding whether the subject may be experiencing an adverse reaction to the substance and to receive responses to the queries, a plurality of vital sign monitors (32 a, 32 b, 32 c) , a substance administering conduit (18) for delivering the substance to the subject's body, and a storage medium that contains at least one controller-accessible database (22, 26, 40) . The at least one controller-accessible database is selected from the group of databases consisting of a) a substance protocol database, b) a subject protocol database, c) a therapy-type protocol database, d) a substance reference library database, e) a system configuration database, f) a history database and g) combinations thereof. The controller is programmed to operate with the user interface and the plurality of vital sign monitors to (i) receive at least one vital sign signal from the plurality of vital sign monitors, (ii) determine, in response to the receipt of the vital sign signal, whether the subject may be experiencing an adverse reaction to the substance, iii) cause the user interface to present at least one of the queries to the subject when the determination in response to (ii) is that the subject may be experiencing an adverse reaction to the substance, and iv) monitor a response by the subject to the at least one presented query to determine whether the subject is suffering an adverse reaction to the substance.